(Total Views: 486)
Posted On: 09/28/2021 9:30:32 PM
Post# of 151825
“no one form the anti "proxy group" has addressed this directly, without calling profanities and changing the subject.”
How do you want it addressed?
We needed the money and thought we would have revenue soon enough to avoid the worst effects.
Unfortunately, CD10/12 didn’t give the results we needed, so we’re dealing with the consequences.
That’s life as a pre-revenue biotech.
Despite what The Group Formerly Known As 13D might try to pretend, there are no easy options. There are trade-offs with every alternative.
In any case, at the end of the day, the share price is still up 500% over the last two years.
So, claims about destruction of shareholder value ring *awfully* hollow to my ears.
How do you want it addressed?
We needed the money and thought we would have revenue soon enough to avoid the worst effects.
Unfortunately, CD10/12 didn’t give the results we needed, so we’re dealing with the consequences.
That’s life as a pre-revenue biotech.
Despite what The Group Formerly Known As 13D might try to pretend, there are no easy options. There are trade-offs with every alternative.
In any case, at the end of the day, the share price is still up 500% over the last two years.
So, claims about destruction of shareholder value ring *awfully* hollow to my ears.


Scroll down for more posts ▼